Roivant Sciences Ltd’s recent filing unveils that its Officer Venker Eric acquired Company’s shares for reported $1.15 million on Jul 21 ’25. In the deal valued at $11.52 per share,100,000 shares were bought.
Then, Venker Eric sold 100,000 shares, generating $1,145,000 in total proceeds. Upon selling the shares at $11.45, the President & COO now owns 1,462,223 shares.
Before that, Ramaswamy Vivek sold 577,007 shares. Roivant Sciences Ltd shares valued at $6,612,500 were divested by the 10% Owner at a price of $11.46 per share. As a result of the transaction, Ramaswamy Vivek now holds 37,284,108 shares, worth roughly $428.02 million.
A number of analysts have revised their coverage, including Wolfe Research’s analysts, who began to cover the stock in mid February with a ‘”an Outperform”‘ rating. Piper Sandler began covering ROIV with “an Overweight” recommendation on January 05, 2024. Deutsche Bank started covering the stock on December 12, 2023. It rated ROIV as “a Buy”.
Price Performance Review of ROIV
On Monday, Roivant Sciences Ltd [NASDAQ:ROIV] saw its stock jump 0.35% to $11.48. Over the last five days, the stock has lost -1.29%. Roivant Sciences Ltd shares have risen nearly 2.04% since the year began. Nevertheless, the stocks have fallen -2.96% over the past one year.
How much short interest is there in Roivant Sciences Ltd?
A steep rise in short interest was recorded in Roivant Sciences Ltd stocks on 2025-06-13, dropping by -4.17 million shares to a total of 45.06 million shares. Yahoo Finance data shows the prior-month short interest on 2025-05-15 was 49.23 million shares. There was a decline of -9.25%, which implies that there is a negative sentiment for the stock.
The most recent change occurred on October 17, 2023 when Guggenheim began covering the stock and recommended ‘”a Buy”‘ rating along with a $17 price target.
